REGENXBIO to Participate in Upcoming Investor Conference

Rhea-AI Summary

REGENXBIO (Nasdaq: RGNX) will participate in the Piper Sandler 37th Annual Healthcare Conference with a fireside chat on Tuesday, December 2, 2025 at 8:30 a.m. ET in New York, NY.

A live webcast will be available in the Investors section of the company's website and an archived replay will be accessible for approximately 30 days following the event.

News Market Reaction – RGNX

+9.98%

21 alerts

+9.98% Session close to close

+3.4% Peak in 1 hr 2 min

$687.97M Market Cap

0.7x Rel. Volume

In the Nov 25 session, RGNX gained 9.98%, reflecting a notable positive market reaction. Argus tracked a peak move of +3.4% during that session. Our momentum scanner triggered 21 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ROCKVILLE, Md., Nov. 25, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conference:

Piper Sandler 37^th Annual Healthcare Conference
Fireside Chat: Tuesday, December 2 at 8:30 a.m. ET
Location: New York, NY

A live webcast of the fireside chat can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the event.

ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.

Contacts:

Dana Cormack
Corporate Communications
dcormack@regenxbio.com 

Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com 

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conference-302625302.html

SOURCE REGENXBIO Inc.

FAQ

When will REGENXBIO (RGNX) present at the Piper Sandler 37th Annual Healthcare Conference?

REGENXBIO will present on Tuesday, December 2, 2025 at 8:30 a.m. ET.

How can investors watch REGENXBIO (RGNX) fireside chat on December 2, 2025?

A live webcast will be available in the Investors section of REGENXBIO's website.

Will REGENXBIO (RGNX) provide a replay of the Piper Sandler fireside chat?

Yes. An archived replay will be available for approximately 30 days after the event.

Where is the Piper Sandler 37th Annual Healthcare Conference taking place for REGENXBIO (RGNX)?

The event location is New York, NY.

What is the ticker symbol for REGENXBIO presenting at the December 2, 2025 conference?

The ticker symbol is RGNX on Nasdaq.

Where on REGENXBIO's site can I find the webcast link for the December 2, 2025 presentation?

The webcast link will be posted in the company's Investors section at www.regenxbio.com.